FindTrial
Sign In

Effect-site concentration of propofol for loss of consciousness in the patients done neoadjuvant chemotherapy for breast cancer.

Pharmacodynamic model of effect-site concentration of propofol for loss of consciousness in the patients done neoadjuvant chemotherapy for breast cancer.

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
CRIS
Registry ID
KCT0005199
Enrollment
50
Registered
2020-07-06
Start date
2019-11-05
Completion date
Unknown
Last updated
2020-07-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Interventions

None listed

Sponsors

Inje University Busan Paik Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: breast cancer sugery with general anesthesia, who did neoadjuvant chemotherapy for breast cancer before surgery, age between 19-75 years old , BMI 18-29.9 kg/m2, ASA class(american society of anesthesiologists classification) 1-3

Exclusion criteria

Exclusion criteria: patiens with neurologic or psychologic disorder history, take sedative drug, chronic alocoholics, high risk patients of airway obstruction during sedation, difficulty in communication, history of neoadjuvant chemotherapy for cancer other than breast cancer before sugery

Design outcomes

Primary

MeasureTime frame
MOAA/S (modified observer’s assessment of alertness/sedation scale) score and BIS score—

Secondary

MeasureTime frame
Plasma concentration of propofol—

Countries

Korea, Republic of

Contacts

Public Contactseunghee ki

Inje University Busan Paik Hospital

Outcome results

None listed

Source: CRIS (via WHO ICTRP) · Data processed: Feb 4, 2026